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Abstract
We report a case of chronic lymphocytic leukemia with a characteristic cytogenetics finding detected
by fluorescent in situ hybridization. This case has deletion in p53 gene in 50% of interphase nuclei
studied in the peripheral blood and polyploidy in 30% of cells. To our knowledge polyploidy is not
commonly reported with chronic lymphocytic leukemia patients.
Introduction
Chronic lymphocytic leukemia (CLL) is a hematopoietic
neoplasm of B-lymphocytes found in the peripheral
blood, bone marrow, and/or lymph nodes [1]. CLL is
the most common leukemia of adults [2]. Cytogenetic
study is useful in predicting clinical outcome. Abnormal-
ities of chromosomes 11 and 17 are associated with poor
prognosis; deletion of 13q is said to have a good
prognosis. Patients are usually asymptomatic at presenta-
tion. Many cases present incidentally with peripheral
blood lymphocytosis. Approximately 80% of patients
have associated lymphadenopathy; approximately 50%
will have an enlarged liver and/or spleen [3].
Loss of tumor protein 53 (TP53) has been associated
withaggressive disease and poor response to therapy in
B-cell chronic lymphocytic leukemia (B-CLL). TP53 is
located at chromosome band 17p13 and its absence can
be detected by fluorescence in situ hybridization (FISH) in
the interphase nuclei of 8-10% patients with B-CLL [4,5].
Previous studies showed that p53 plays a central role in
G1 and DNA damage checkpoints, thus contributing to
genomic stability [6].
Case presentation
A 60-year Egyptian female presented with splenomegaly
and lymphadenopathy. The laboratory tests showed
Hb: 11 g/dL, TLC: 12 × 10
9/L, PLT: 130 × 10
9/L, absolute
lymphocyte: 8 × 10
9/L, relative lymphocyte: 73 × 10
9/L,
bone marrow lymphocyte: 78 × 10
6/mL. Biochemical test
revealed slight increase in the lactic dehydrogenase (LDH):
260 IU/l (normal up to 240 IU/L) and Ca: 7.5 mg/dL. The
lymphocytes of the bone marrow express an immuno-
phenotype suggestive of B-cell lymphoproliferative type.
The immunophenotype of leukemic cells was CD19: 68%,
CD22: 60%, CD22: 57%, CD23: 52%, CD79b: 58.5%. The
myeloid markers were negative. Also HLA-DR was 71%
and CD38 was 58.2%.
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unsuccessful culture for chromosomal study. FISH study
was done using (DLEU (13q14)/p53 (17p13) red/green
Kreatech) probe, the FISH revealed deletion in p53 in 50%
of cells, and 3-5 copies of 13q14 in 30% of cells. First, it
was thought that there is gene amplification in this region,
which is a very rare finding. So, FISH study was done using
(Sub Telomere 13qter green) probe to exclude polosomy.
This also revealed 3-5 signals in 30% of cells. Then
polyploidy was suggested and confirmed by (Sub Telo-
mere 1pter green) which also gave 3-5 copies of 13q14 in
30% of cells.
Discussion
Polyploidy could be explained by the deletion in the p53
gene which is essential in the regulation of cell cycle and
mitotic division. There is much evidence linking p53 and
development of polyploidy [7]. Recently, it was shown
that the transcriptional induction of p53 by mitotic
checkpoint activation is essential in protecting cells from
developing abnormal levels of chromosome ploidy caused
by mitotic failure. Studies have shown that p53 deficien-
cies induce insufficient mitosis arrest, compromise apop-
tosis, and can cause profound aneuploidy. Despite this,
the molecular mechanisms implicating p53 mitotic
regulation with a chromosomal instability phenotype is
not yet clearly demonstrated. However, this might be
accompanied by other gene deletion such as p73 that is
also key regulatory genes in between chromosomal
instability and cancer development. It should be realized
that p53 defects could lead to highly unstable karyotypes
that might ultimately push cells towards malignant
transformation (6). Moreover, CLL patients with P53
gene deletion progress rapidly, respond poorly to therapy,
and do not survive for long [8,9].
Conclusion
In conclusion, the genetic instability is caused by deletion
in the p53 gene, the factor that led to excessive DNA
replication. To our knowledge polyploidy is not com-
monly reported with CLL patients.
Patient’s perspective
I suffered from leukemia, and then I was referred to do
cytogenetic analysis which revealed a chromosomal defect.
Then I was given genetic counseling and was told that I
need follow up.
Abbreviations
B-CLL, B-cell chronic lymphocytic leukemia; CLL, chronic
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Figure 1. Deletion in p53 (green) and multiple copies of
13q14 (red).
Figure 2. 4 signals of sub telomere 1p.
Figure 3. Five copies of sub telomere 13q.
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